TAK-733
Title | Journal |
---|---|
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. | Investigational new drugs 20170101 |
Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
MEK and the inhibitors: from bench to bedside. | Journal of hematology & oncology 20130101 |
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. | Bioorganic & medicinal chemistry letters 20110301 |